RT Journal Article
SR Electronic
T1 Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and correlation with integrated, multiomic analysis in the NIBIT-M4 trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.02.09.23285227
DO 10.1101/2023.02.09.23285227
A1 Teresa Maria Rosaria Noviello
A1 Anna Maria Di Giacomo
A1 Francesca Pia Caruso
A1 Alessia Covre
A1 Giovanni Scala
A1 Maria Claudia Costa
A1 Sandra Coral
A1 Wolf H. Fridman
A1 Catherine Sautès-Fridman
A1 Roberta Mortarini
A1 Silvia Brich
A1 Giancarlo Pruneri
A1 Elena Simonetti
A1 Maria Fortunata Lofiego
A1 Davide Bedognetti
A1 Andrea Anichini
A1 Michele Maio
A1 Michele Ceccarelli
A1 the EPigenetic Immune-oncology Consortium AIRC (EPICA) investigators
YR 2023
UL http://medrxiv.org/content/early/2023/02/10/2023.02.09.23285227.abstract
AB Association of DNA hypomethylating agents (DHA) with immune-checkpoint inhibitors (ICI) is a promising strategy to improve efficacy of ICI-based therapy. Here we report the five-year clinical outcome and an integrated multi-omics analysis of pre- and on-treatment lesions from advanced melanoma patients enrolled in the phase Ib NIBIT-M4 study, a dose-escalation trial of the DHA agent guadecitabine combined with ipilimumab. With a minimum follow-up of 45 months the median OS was 25.6 months; the 5-year OS rate was 28.9% and the median DoR was 20.6 months. Specific genomic features and extent of T and B cellmediated immunity discriminated lesions of responding compared to non-responding patients. Enrichment for proliferation and EMT-related gene programs, and immune escape mechanisms characterized lesions from non-responding patients. Integration of a genetic immunoediting index (GIE) with an adaptive immunity signature (ICR) stratified patients/lesions into four distinct subsets and discriminated 5-year OS and PFS. These results suggest that coupling of immunoediting with activation of adaptive immunity is a relevant requisite for achieving long term clinical benefit by epigenetic immunomodulation in advanced melanoma patients.Competing Interest StatementAMDG has served as consultant and/or advisor to Incyte, Pierre Fabre, Glaxo Smith Kline, Bristol-Myers Squibb, Merck Sharp Dohme, and Sanofi and has received compensated educational activities from Bristol Myers Squibb, Merck Sharp Dohme, Pierre Fabre and Sanofi. W.H. Fridman has served as consultant and/or advisor to Astra Zeneca, Adaptimmune, Catalym, OOSE Immunotherapeutics, and Novartis, and reports receiving speakers bureau honoraria from Bristol-Myers Squibb. MM has served as consultant and/or advisor to Roche, Bristol-Myers Squibb, Merck Sharp Dohme, Incyte, AstraZeneca, Amgen, Pierre Fabre, Eli Lilly, Glaxo Smith Kline, Sciclone, Sanofi, Alfasigma, and Merck Serono; and own shares in Theravance and Epigen Therapeutics, Srl. Other authors have nothing to declare.Clinical TrialNCT02608437Funding StatementThe research leading to these results has received funding from AIRC under 5 per Mille 2018 ID.21073 project P.I. Maio Michele, G.L. Anichini Andrea, G.L. Ceccarelli Michele. The research leading to these results has received funding from AIRC under IG 2018 ID. 21846 project P.I. Ceccarelli Michele. This work was also supported by the Italian Ministry of Research Grant PRIN 2017XJ38A4_004.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was conducted in accordance with the ethical principles of the Declaration of Helsinki and the International Conference on Harmonization of Good Clinical Practice. The protocol was approved by the independent ethics committee of the University Hospital of Siena (Siena, Italy). All participating patients (or their legal representatives) provided signed-informed consent before enrolment. The trial was registered with European Union Drug Regulating Authorities ClinicalTrials EudraCT, number 2015-001329-17, and with ClinicalTrials.gov, number NCT02608437.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe processed NanoString dare are available via the GEO accession number: GSE211645 [https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE211645; token mjghgimevhmpbkx]. Raw data of Whole Exome Sequencing, RNA-Sequencing and Reduced Representation Bisulfite Sequencing are available on the European Genome-phenome Archive under accession number EGAS00001006736. https://ega-archive.org/studies/EGAS00001006736